Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.

Aktas, Gokmen; Kus, Tulay; Emin Kalender, Mehmet; Kervancioglu, Selim; Sevinc, Alper; Kul, Seval; Camci, Celaletdin

Aktas, Gokmen; Kus, Tulay; Emin Kalender, Mehmet; Kervancioglu, Selim; Sevinc, Alper; Kul, Seval; Camci, Celaletdin.

Affiliation

Aktas G; Gaziantep University, School of Medicine, Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, Gaziantep, Turkey.

J BUON ; 22(1): 150-156, 2017.

Article in En | MEDLINE | ID: mdl-28365948

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Hepatocellular/therapy; Chemoembolization, Therapeutic; Liver Neoplasms/therapy; Niacinamide/analogs & derivatives; Phenylurea Compounds/therapeutic use; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular/mortality; Combined Modality Therapy; Female; Humans; Liver Neoplasms/mortality; Male; Middle Aged; Niacinamide/therapeutic use; Retrospective Studies; Sorafenib

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Chemoembolization, Therapeutic / Niacinamide / Carcinoma, Hepatocellular / Liver Neoplasms / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J BUON Journal subject: NEOPLASIAS Year: 2017 Type: Article Affiliation country: Turkey

Search on Google

XML

PubMed Links